Characterizing the autologous fat graft microenvironment resulting from differential intraoperative processing techniques: A comparative analysis and its clinical implications
Project Number1R21CA287340-01A1
Former Number1R21CA287340-01
Contact PI/Project LeaderOTTERBURN, DAVID Other PIs
Awardee OrganizationWEILL MEDICAL COLL OF CORNELL UNIV
Description
Abstract Text
1 Project Summary
2
3 Autologous fat grafting is the transfer of fat from one anatomical region to another and is commonly used in
4 breast reconstruction after mastectomy. Accurate prediction of graft retention remains an enduring clinical
5 problem, as resorption is reported to range between 10% to 50% in the literature. While there are several devices
6 available for fat grafting, no randomized, controlled trials have been completed to compare outcomes between
7 them, including volume retention and factors that would affect volume retention. Given the lack of evidence-
8 based guidelines, the decision of how best to process graftable fat remains up to physician preference. Moreover,
9 much work fails to assess the microscopic alterations to the grafted tissue resulting from each processing
10 technique, the study of which might reveal important predictive factors of complications or graft take. In response,
11 we are seeking to compare outcomes between three fat grafting devices which process the lipoaspirate in different
12 ways before it is injected into the graft site. We will utilize fat samples collected from patients undergoing fat grafting
13 who have been enrolled in an ongoing randomized, controlled trial to receive fat processed by techniques that
14 actively wash and filter the fat, known as “active closed wash and filtration” (ACWF), passively filter the fat
15 through a collecting system with minimal processing, known as a “passive low pressure closed system” (LPCS),
16 or actively wash and filter the fat with the addition of surfactant, known as “active wash and filtration plus
17 surfactant” (AWFPS). Originally, the ACWF and LPCS devices were compared to standard decantation; however
18 interim analysis showed superior volume retention with the ACWF and LPCS devices. Standard decantation has been
19 replaced with AWFPS to identify the optimal fat grafting device to use for patients. We will take the lipoaspirate that has
20 been harvested and processed via ACWF, LPCS, or AWPS, and inject a predefined quantity into the dorsa of
21 immunocompromised mice. We will assess the volume and projection of the grafted material in the mice at 1, 2,
22 and 3 months, as the literature states that reabsorption happens within the first 3 months and then the graft
23 becomes stable. We will also characterize the cellular environment around and within each graft after 3 months,
24 including any immune or inflammatory response as well as the viability and potential hormonal activity of the
25 grafted fat. Further, we will compare the retention rates and complication profiles observed in our mouse models
26 with those of their patient counterparts in the companion trial to provide further confirmation of any preliminary
27 conclusions drawn. Lastly, we will complete this analysis with a small subset of humanized mice as well in order
28 to compare outcomes and the ability to measure volume retention in immunocompromised versus humanized
29 mice. Measurement of volume retention of human lipoaspirate has not yet been documented in humanized mice,
30 and including a pilot study would allow us to assess immunogenicity effects on volume retention of lipoaspirate
31 and whether future studies of this nature could be completed in humanized mice. Immunogenicity effects will be
32 assessed by measuring angiogenesis in the grafted fat after 3 months and comparing between mouse species.
Public Health Relevance Statement
Project Narrative
This project holds the potential to establish best-practice guidelines for surgeons seeking to safely and reliably
use a patient's own fatty tissue to improve outcomes in breast reconstruction. While many methods of using
patient-derived fat for this purpose exist, there is a lack of consensus in the surgical community regarding which
method is superior, and this study would provide new and important data characterizing not only the clinical
outcomes of three of the most common fat processing methods used, but also highly impactful, time-dependent
information on the cellular-level differences in the fat after it is processed by each method. Finally, this study will
evaluate differences in the levels of estrogen-producing proteins in the processed fat that is ultimately placed in
close proximity to what was, in many cases, estrogen-responsive cancer, any differences between which have
yet to be studied and hold the potential for direct influence over clinical practice should they prove substantial.
No Sub Projects information available for 1R21CA287340-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R21CA287340-01A1
Patents
No Patents information available for 1R21CA287340-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R21CA287340-01A1
Clinical Studies
No Clinical Studies information available for 1R21CA287340-01A1
News and More
Related News Releases
No news release information available for 1R21CA287340-01A1
History
No Historical information available for 1R21CA287340-01A1
Similar Projects
No Similar Projects information available for 1R21CA287340-01A1